-
2024-520446-31-00
5
2026-05-27
Participants with overweight or obesity, and type 2 diabetes
-
2025-522669-32-00
5
2025-12-18
Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lym
-
2022-500273-14-00
10
2023-07-17
Atherosclerotic cardiovascular disease in patients with ESKD
-
2024-516652-18-00
5
2025-10-10
Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
-
2024-519525-38-00
5
2025-08-22
Heart failure
-
2024-519928-24-00
4
2025-08-21
Myelodysplastic Syndrome
-
2024-519945-31-00
5
2025-08-21
Type 1 Diabetes
-
2024-517247-31-00
5
2025-07-07
Newly Diagnosed Higher Risk Myelodysplastic Syndrome
-
2024-511495-32-00
5
2025-04-16
Chronic Phase Chronic Myeloid Leukemia
-
2023-509706-30-00
5
2024-10-18
Heart failure (HF)
-
2023-508423-13-00
5
2024-07-01
Chronic lymphocytic leukemia
-
2022-502193-16-00
5
2023-11-14
Chronic lymphocytic leukemia, Multiple Myeloma and Non-Hodgkin Lymphom
-
2023-503224-66-00
5
2023-10-31
Atrial Fibrillation
-
2024-517206-28-00
6
2022-09-21
Recent myocardial infarction associated with iron deficient
-
2023-505438-85-00
5
2022-01-12
Acute myocardial infarction (AMI)
-
2022-502781-24-01
5
2024-06-05
ASCVD - Atherosclerotic Cardiovascular Disease
-
2022-501419-15-00
5
2023-08-23
Atrial Fibrillation
-
2022-500138-27-01
5
2023-02-28
Multiple Myeloma
-
2023-506929-11-00
5
2022-10-17
Overweight and obesity
-
2024-516714-37-00
5
2022-01-19
Chronic obstructive pulmonary disease (COPD)
-
2023-507697-40-00
5
2021-07-05
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
-
2023-509976-40-00
5
2018-05-28
Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
-
2024-512115-50-00
4
2016-06-22
Relapsed/Refractory DLBCL
-
2023-509412-28-00
4
2024-07-26
Type 2 Diabetes